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A study of diketopiperazines as electron-donor initiators in 
transition metal-free haloarene-arene coupling 
Florimond Cumine,a Shengze Zhou,a Tell Tuttle,*a and John. A. Murphy*a  
Several diketopiperazines  have been shown to promote carbon-carbon coupling between benzene and aryl halides in the 
presence of potassium tert-butoxide and without the assistance of a transition metal catalyst.  The structure of the 
diketopiperazine has an influence on its reductive potential and can help to promote the coupling of the more challenging 
aryl bromides with benzene.
Introduction  
 
Over the past ten years, transition metal-free cross coupling 
reactions of aryl halides with benzenes have become a major 
interest since they were first observed by Itami.1,2 These 
reactions require a base (typically potassium tert-butoxide) 
and an additive.3-16 Whilst organic additives are not always 
used,10,11,15 they significantly enhance reaction efficiency in 
terms of yield and time. The widely-accepted mechanism 
involved in these coupling reactions is base-promoted 
homolytic aromatic substitution (BHAS).17 A molecule of 
halobenzene 1 receives an electron and forms an aryl radical 2 
which adds to benzene to yield an intermediate 
cyclohexadienyl radical 3. Deprotonation by the base yields 
radical anion 4, which gives an electron to another 
halobenzene 1, propagating the chain, and simultaneously 
releasing biaryl product 5 (Scheme 1). 
 
The initiation process, in other words, the formation of aryl 
radical 2 from aryl halide 1 to start the chain, has been a main 
field of research for our group.18-20 Understanding the nature 
of this process is the key to extrapolating this transition metal-
free cross-coupling reaction to aryl bromides and chlorides 
which remain more challenging substrates than aryl iodides. 
We recently reported a study on organic additives and 
mechanistic studies on their ability to initiate cross-coupling 
reactions under basic conditions.19 We have been particularly 
interested in amino acids as additives since the report of 
proline and sarcosine as initiators under basic conditions.11 
Amino acids can undergo condensation to form peptides21 and 
also cyclic dipeptides under microwave conditions.22 These 
cyclic dipeptides, usually called diketopiperazines (DKP), once 
deprotonated, could act as electron donors. A N,N ?-dipropyl 
diketopiperazine 6 has already been reported by our group 
and was used as an electron donor under basic conditions.19 
This DKP was found to be a good initiator of coupling reactions 
with iodobenzenes. Herein, we report diketopiperazines 7-10, 
with different substituents on the nitrogens, all including a 
phenyl ring in order to improve the DKP solubility in benzene. 
These DKPs were found to be good initiators for the coupling 
of iodobenzenes and, for some of them, good initiators for the 
coupling of bromobenzenes with benzene (Figure 1). 
 
Scheme 1 
 
 
 
 
 
 
 
 
 
 
 
              
 
 
 
Fig. 1 Diketopiperazines used as precursors to electron donors for coupling 
reaction of iodo and bromobenzenes with benzene.  
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Results and discussion 
The diketopiperazines 7-10 were each made following the 
same strategy: amide formation by reaction of an amine with 
an acyl chloride followed by alkylation reaction under basic 
conditions (Scheme 2).19 This easy process afforded the 
expected diketopiperazines in good to excellent yields. The 
coupling reactions of several halobenzenes with benzene were 
made using a substoichiometric amount of DKP, with an excess 
of potassium tert-butoxide used to deprotonate the DKP, 
forming an enolate that can act as an electron donor (Scheme 
3). 
 
Scheme 2 
 
 
 
 
 
 
Scheme 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In principle, the monoanions 20-23 could undergo a second 
deprotonation leading to a dianion species, as we recently 
reported the formation of dianions with several additives such 
as pyridine carbinols.23 We also reported19 that the DKP 24, 
synthesized so that only one position is available for 
deprotonation, is able to promote the coupling reaction of 
iodobenzenes with benzene efficiently. Therefore, we propose 
that only one deprotonation happens and that this is 
necessary and sufficient for the reaction to be initiated. 
 
 
  
 
 
 
 
 
 
Fig. 2   General reaction and substrate scope. 
 
Once synthesized, each DKP was engaged as an initiator in 
cross-coupling reactions of unactivated halobenzenes with 
benzene (Figure 2).  
 
Table 1: Coupling reaction of aryl iodides with benzene 
initiated by diketopiperazines 
 
Entry Aryl Halide DKP Product Yielda 
(%) 
1 25 X = I, R = H 7 37 R = H 80 
2 25 X = I, R = H 8 37 R = H 60 
3 25 X = I, R = H 9 37 R = H 74 
4 25 X = I, R = H 10 37 R = H 70 
5 26 X = I, R = o-OMe 7 38 R = o-OMe 64 
6 26 X = I, R = o-OMe 8 38 R = o-OMe 51 
7 26 X = I, R = o-OMe 9 38 R = o-OMe 59 
8 26 X = I, R = o-OMe 10 38 R = o-OMe 64 
9 27 X = I, R = m-OMe 7 39 R = m-OMe 61 
10 27 X = I, R = m-OMe 8 39 R = m-OMe 49 
11 27 X = I, R = m-OMe 9 39 R = m-OMe 70 
12 27 X = I, R = m-OMe 10 39 R = m-OMe 69 
13 28 X = I, R = p-OMe 7 40 R = p-OMe 61 
14 28 X = I, R = p-OMe 8 40 R = p-OMe 64 
15 28 X = I, R = p-OMe 9 40 R = p-OMe 80 
16 28 X = I, R = p-OMe 10 40 R = p-OMe 72 
17 29 X = I, R = o-Me 7 41 R = o-Me 69 
18 29 X = I, R = o-Me 8 41 R = o-Me 44 
19 29 X = I, R = o-Me 9 41 R = o-Me 57 
20 29 X = I, R = o-Me 10 41 R = o-Me 56 
21 30 X = I, R = m-Me 7 42 R = m-Me 64 
22 30 X = I, R = m-Me 8 42 R = m-Me 57 
23 30 X = I, R = m-Me 9 42 R = m-Me 70 
24 30 X = I, R = m-Me 10 42 R = m-Me 67 
25 31 X = I, R = p-Me 7 43 R = p-Me 60 
26 31 X = I, R = p-Me 8 43 R = p-Me 60 
27 31 X = I, R = p-Me 9 43 R = p-Me 78 
28 31 X = I, R = p-Me 10 43 R = p-Me 68 
a Isolated yield 
 
Additive 7 was particularly efficient to promote the coupling of 
iodobenzenes to benzene however, its efficiency for the 
coupling of bromobenzenes to benzene was not satisfactory 
(Table 1 and Table 2). We were pleased to find that additive 8 
was efficient with both iodobenzenes and bromobenzenes 
(except for the particular case of 3-bromoanisole 34). This 
made us consider the effect of the N-substituent on the 
reductive ability of the electron donors 20-23. The phenyl 
substituent of 20 decreases the reductive capacity due to its 
withdrawing inductive effect.24 Computational optimization25-
26 of the structure of 20 shows there is no co-planarity of the 
two arene rings with the centre ring, and thus little or no 
electron delocalisation by resonance (Figure 3). We also 
checked the spin density of 20
.
 and found that it is localised 
only on its central ring and not on the phenyl substituents. 
DKPs 9 and 10 also promoted the coupling reaction of aryl 
bromides with benzene but not as efficiently as DKP 8. Their 
efficiency with aryl bromides shows a stronger reductive effect 
than 20 since the inductive effect of the N-substituents of 21-
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23 is donating.24 We also computationally optimized the 
electron transfer reaction27 involving these initiators and 
found lower barriers for 21-23, derived from 8-10, than 20, 
derived from 7 which is in accordance with our experimental 
results (Table 3). However, none of these DKP donors was able 
to promote the coupling reaction of chlorobenzenes or 
fluorobenzenes to benzene. 
 
Table 2: Coupling reaction of aryl bromides with benzene 
initiated by diketopiperazines 
 
Entry Aryl Halide DKP Product Yielda 
(%) 
1 32 X = Br, R = H 7 37 R = H 14 
2 32 X = Br, R = H 8 37 R = H 68 
3 32 X = Br, R = H 9 37 R = H 32 
4 32 X = Br, R = H 10 37 R = H 32 
5 33 X = Br, R = o-OMe 7 38 R = o-OMe 36 
6 33 X = Br, R = o-OMe 8 38 R = o-OMe 50 
7 33 X = Br, R = o-OMe 9 38 R = o-OMe 48 
8 33 X = Br, R = o-OMe 10 38 R = o-OMe 59 
9 34 X = Br, R = m-OMe 7 39 R = m-OMe 2 
10 34 X = Br, R = m-OMe 8 39 R = m-OMe 2 
11 34 X = Br, R = m-OMe 9 39 R = m-OMe 2 
12 34 X = Br, R = m-OMe 10 39 R = m-OMe 2 
13 35 X = Br, R = p-OMe 7 40 R = p-OMe 13 
14 35 X = Br, R = p-OMe 8 40 R = p-OMe 56 
15 35 X = Br, R = p-OMe 9 40 R = p-OMe 21 
16 35 X = Br, R = p-OMe 10 40 R = p-OMe 29 
17 36 X = Br, R = p-Me 7 43 R = p-Me 12 
18 36 X = Br, R = p-Me 8 43 R = p-Me 47 
19 36 X = Br, R = p-Me 9 43 R = p-Me 29 
20 36 X = Br, R = p-Me 10 43 R = p-Me 37 
a Isolated yield 
 
In the particular case of 3-bromoanisole 34, very low yields of 
the coupling product with benzene were found, no matter 
which DKP was used. Instead, we found a selective formation 
of 1-(tert-butoxy)-3-methoxybenzene 44 resulting from a 
selective benzyne formation, by action of potassium tert-
butoxide on 3-bromoanisole 34, followed by a selective 
nucleophilic addition of tert-butoxide to the benzyne 45 
(Scheme 4). This particular selectivity in both the formation of 
the benzyne and the addition of tert-butoxide is known27 and 
can be explained as follows: of the two protons leading to the 
formation of benzyne by their elimination, the more acidic one 
is ortho to the methoxy group due to the attractive inductive 
effect of this substituent. Also, the potassium can coordinate 
with the methoxy group and direct the selective deprotonation 
on its ortho position. The addition of tert-butoxide to benzyne 
45 is meta to the methoxy group as this leads to the formation 
of the more stable carbanion due to the inductive attractive 
effects of both the methoxy and tert-butoxy groups. The 
selectivity of the addition is also in accordance with 
computational results published by Houk and Garg29 who 
showed that the nucleophilic addition will happen on the 
aryne terminus with the larger internal angle which, in the 
case of a mono-substituted benzyne such as 45, is at the meta-
position of the substituent. Our optimized structure of 45 
ƐŚŽǁĞĚƚŚĞƐĂŵĞƌĞƐƵůƚǁŝƚŚĂŶ ŝŶƚĞƌŶĂůĂŶŐůĞŽĨ  ? ? ?ȗĂƚ ƚŚĞ
meta ƉŽƐŝƚŝŽŶ ĂŶĚ  ? ? ?ȗ Ăƚ ƚŚĞortho position. An interesting 
fact is, while the benzyne formation/nucleophilic addition was 
favored over the actual coupling reaction with 3-bromoanisole 
34, the opposite happened with 3-iodoanisole 27 where the 
coupling with benzene was not affected by any other reaction. 
This shows again that iodobenzenes are more reactive 
substrates toward electron transfer than bromobenzenes due 
to the high reactivity of the C-I bond. 
 
Anion 20 
 
 
 
 
 
 
 
 
Radical 20
.
 
 
 
 
 
 
 
Anion 21 
 
 
 
 
 
Radical 21
.
 
 
 
 
 
 
 
 
Fig. 3 Optimized structures of anions 20 and 21 and radicals 20. and 21. (spin 
density shown in blue). 
The ability of aryl halides to generate benzynes30 should not be 
underestimated and it is not a process only seen with meta-
haloanisoles. In fact, it is a process that occurs during all the 
reactions we report. The key to make the benzyne formation a 
side-reaction is the use of an additive such as the several DKPs 
we report here (except for the particular case of 3-
bromoanisole 34). When we reacted 4-bromoanisole 35 with 
DKP 8 under our general conditions, we found not only the 
coupling product 40 but also two regioisomers 44 and 46 
resulting from the nucleophilic addition of tert-butoxide on a 
benzyne ring (Scheme 5). 
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The addition of tert-butoxide was also observed when 
bromobenzene 32 was used under the same conditions and 
formed tert-butoxybenzene 48.  
 
Table 3: Energies of electron transfer reactionsa 
 
Entry Substrate Initiator ο۵כ ο۵ܚ܍ܔ 
1 25 X = I, R = H 20 31.3 22.9 
2 25 X = I, R = H 21 28.6 18.5 
3 25 X = I, R = H 22 27.7 17.0 
4 25 X = I, R = H 23 27.0 15.1 
5 28 X = I, R = p-OMe 20 35.7 27.7 
6 28 X = I, R = p-OMe 21 32.9 23.4 
7 28 X = I, R = p-OMe 22 31.9 21.8 
8 28 X = I, R = p-OMe 23 31.2 20.0 
9 32 X = Br, R = H 20 31.1 22.8 
10 32 X = Br, R = H 21 28.4 18.5 
11 32 X = Br, R = H 22 27.4 16.9 
12 32 X = Br, R = H 23 26.8 15.0 
13 35 X = Br, R = p-OMe 20 34.3 24.9 
14 35 X = Br, R = p-OMe 21 31.7 20.5 
15 35 X = Br, R = p-OMe 22 30.7 19.0 
16 35 X = Br, R = p-OMe 23 30.0 17.1 
a Energies reported in kcal/mol 
 
Scheme 4 
 
 
 
 
 
 
 
 
 
 
 
 
When increasing the temperature of the reaction to see if this 
could improve the coupling reaction with bromobenzenes and 
eventually chlorobenzenes (chlorobenzene 49 and 4-
chloroanisole 50 were tested), noted that an increased 
temperature actually disfavoured the coupling reaction and 
did not alter the benzyne formation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5   Evidence of benzyne formation.a 
a Yields calculated from 1H NMR using 1,3,5-trimethoxybenzene as an internal 
standard. 
 
Chlorobenzenes as substrates along with a DKP donor initiator 
never afforded the desired coupling product. These less 
reactive substrates toward metal-free cross-coupling reactions 
remain a challenge that will require even more powerful 
organic electron donors to be overcome. The benzyne 
formation from aryl halides under basic conditions can also 
alter the cross-coupling reaction of electron-poor aryl halides 
with benzene. On one hand, 4-iodobenzonitrile 51 and 4-
bromobenzonitrile 52 afforded the expected coupling product 
53 with benzene when DKPs 7 and 8 were used (Scheme 6), 
with a moderate amount of benzyne adducts observed only 
when DKP 7 was used with 4-bromobenzonitrile 52 alongside 
with a small amount of 53. 
 
 
 
 
 
Scheme 6   Coupling reaction of 4-halobenzonitriles with benzene.  
a For this reaction, 53 was recovered in an inseparable mixture with the benzyne 
adducts (see experimental details for more information). 
 
On the other hand, 4-iodobenzotrifluoride 54 and 4-
bromobenzotrifluoride 55 did not afford the coupling product 
with benzene but only the two benzyne adducts 56 and 57 
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(Scheme 7). The strong attractive inductive effect of the 
trifluoromethyl group24 must result in an increased acidity of 
the protons ortho to the halide thus in an easier benzyne 
formation. 
 
 
 
 
Scheme 7   4-halobenzotrifluorides as non-reactive substrates toward metal-free 
cross-coupling reaction with benzene promoted by DKPs.  
These last results show that some electron poor aryl halides 
might favour the benzyne mechanism over the cross-coupling 
reaction thus not being suitable substrates for metal-free 
cross-coupling reactions involving electron transfer under 
basic conditions. 
Conclusions 
Effective additives for initiating the cross-coupling reaction of 
iodo and bromoarenes with benzene in the presence of 
potassium tert-butoxide were found. These additives are N,N ?-
disubstituted diketopiperazine derivatives and may arise from 
secondary amino acids, such as proline, under the conditions 
of the cross coupling reactions. Some of these novel additives 
mediate the transition metal-free cross coupling reactions not 
only of unactivated aryl iodides but also aryl bromides with 
benzene, and this depends on the substituents attached to the 
nitrogens of the diketopiperazines. Achieving the same 
reaction with aryl chlorides remains a challenging process and 
likely requires even more powerful electron donors. Under 
current protocols, chlorobenzenes undergo preferential 
formation of benzyne rather than the cross-coupling reaction. 
 
 
Experimental Section 
 
General experimental information 
All the reactions were performed in oven-dried apparatus and 
preparation of the diketopiperazines was carried out under argon 
atmosphere using dry solvents. Tetrahydrofuran, dichloromethane 
and hexane were dried with a Pure-Solv 400 solvent purification 
system by Innovative Technology Inc., U.S.A. A glove box 
(Innovative Technology Inc., U.S.A.) was uƐĞĚ ƚŽ ŝŶƚƌŽĚƵĐĞ Ăůů ƚŚĞ
ƌĞĂĐƚĂŶƚƐ ŝŶƚŽĂƉƌĞƐƐƵƌĞ ƚƵďĞ ?ůů ƚŚĞƌĞĂŐĞŶƚƐǁĞƌĞďŽƵŐŚƚĨƌŽŵ
ĐŽŵŵĞƌĐŝĂůƐƵƉƉůŝĞƌƐĂŶĚƵƐĞĚǁŝƚŚŽƵƚĨƵƌƚŚĞƌƉƵƌŝĨŝĐĂƚŝŽŶ ?ƵŶůĞƐƐ
ƐƚĂƚĞĚ ŽƚŚĞƌǁŝƐĞ ?  ƺĐŚŝ ƌŽƚĂƌǇ ĞǀĂƉŽƌĂƚŽƌ ǁĂƐ ƵƐĞĚ ƚŽ
concentrate the reaction mixtures. Thin layer chromatography (TLC) 
was performed using aluminium-backed sheets of silica gel and 
visualized under a UV lamp (254 nm).  Column chromatography was 
performed to purify compounds by using silica gel 60 (200-400 
mesh). 
Proton NMR (1H) spectra was recorded at 400 MHz on a Bruker DPX 
400 spectrometer. Carbon NMR (13C) spectra were recorded at 100 
MHz. The chemical shifts are quoted in parts per million (ppm) by 
taking tetramethylsilane as a reference (ߜ = 0) but calibrated on the 
residual non-deuterated solvent signal. Signal multiplicities are 
abbreviated as: s, singlet; d, doublet; t, triplet; q, quartet; qt, 
quintet; m, multiplet; bs, broad singlet; coupling constants are given 
in Hertz (Hz). 
Infra-Red spectra were recorded using a Shimadzu FT-IR 
Spectrophotometer (Model IRAffinity-1) with a MIRacle Single 
Reflection Horizontal ATR Accessory. Melting points were 
determined on a Gallenkamp Melting point apparatus. High 
resolution mass spectra were recorded at EPSRC National Mass 
Spectrometry Service Centre, Swansea. The spectra were recorded 
using electron ionization (EI), chemical ionization (CI), fast atom 
bombardment (FAB) or electrospray ionization (ESI) techniques as 
stated for each compound. 
 
Synthesis of Diketopiperazines 7-10 
 
Preparation of 1,4-diphenylpiperazine-2,5-dione 7 [R = Ph] 
To a solution of freshly distilled aniline 12 (1.0 equiv, 6.0 g, 64.43 
mmol) and triethylamine (1.1 equiv, 9.87 ml, 70.87 mmol) in DCM 
(100 mL) was slowly added chloroacetyl chloride 11 (1.1 equiv, 5.64 
ml, 70.87 mmol). 
After addition, the mixture was stirred at RT for 45 min and 
quenched with water (70 mL) and extracted with DCM (3 x 40 mL). 
The combined organic phases were washed with hydrochloric acid 
(2M, 100 mL) and with a saturated solution of NaHCO3 (100 mL). 
The organic phase was dried over Na2SO4, filtered and concentrated 
to afford 2-chloro-N-phenylacetamide 16 as a brown/yellow solid 
(10.52 g, 62.02 mmol, 96.25%). M.Pt: 118-120 °C (lit. 122-125 °C).31 ߜH (400 MHz, CDCl3): 4.19 (2H, s, CH2), 7.17 (1H, m, ArH), 7.36 (2H, 
m, ArH), 7.55 (2H, m, ArH), 8.23 (1H, bs, NH). ߜC (101MHz, CDCl3): 
43.0, 120.3, 125.4, 129.3, 136.8, 163.9. IR (NEAT) ʆA?688, 748, 856, 
1249, 1342, 1442, 1496, 1556, 1600, 1668, 3097, 3143, 3207, 3265 
cm-1. m/z (APCI) calcd for C8H9ClNO [M+H]+: 170.0367, found: 
170.0366. 
Sodium hydride (60% in oil, 1.0 equiv, 2.47 g, 62.02 mmol) was 
washed with dry hexane (2 x 20 mL) and the hexane was removed 
via cannula. Dry THF (50 mL) was added to the sodium hydride and 
the mixture was cooled to 0 °C. A solution of 16 (1.0 equiv, 10.52 g, 
62.02 mmol) in dry THF (150 mL) was slowly added. The resulting 
mixture was stirred from 0 °C to RT for 17 h. 
Water (200 mL) was added and the resulting mixture was filtered 
on a funnel to isolate the product as a solid, which was washed with 
DCM. The filtrate was extracted three times with DCM. The organic 
phase and the isolated solid were combined and concentrated to 
afford the product 1,4-diphenylpiperazine-2,5-dione 7 as a pale 
brown solid (8.09 g, 30.38 mmol, 97.9%). M.Pt: 262-264 °C (lit. 266-
267 °C).32 ߜH (400 MHz, CDCl3): 4.55 (4H, s, CH2), 7.32-7.38 (6H, m, 
ArH), 7.44-7.49 (4H, m, ArH). ߜC (100MHz, CDCl3): 53.6, 125.1, 
127.7, 129.6, 139.7, 164.1. IR (NEAT) ʆ A?  ? ? ? ?  ? ? ? ?  ? ? ? ? ?  ? ? ? ? ?
1334, 1431, 1450, 1469, 1496, 1591, 1651, 2947, 3059 cm-1. m/z 
(APCI) calcd for C16H15N2O2 [M+H]+: 267.1128, found: 267.1130.  
 
Preparation of 1,4-dibenzylpiperazine-2,5-dione 8 [R=CH2Ph] 
To a solution of benzylamine 13 (1.0 equiv, 1.0 g, 9.33 mmol) and 
triethylamine (1.1 eq, 1.43 mL, 10.27 mmol) in DCM (30 mL) was 
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slowly added chloroacetyl chloride (1.1 equiv, 0.82 mL, 10.27 
mmol). 
After addition, the mixture was stirred at RT for 45 min and 
quenched with water (20 mL) and extracted with DCM (3 x 20 mL). 
The combined organic phases were washed with hydrochloric acid 
(2M, 20 mL) and with a saturated solution of NaHCO3 (20 mL). 
The organic phase was dried over Na2SO4, filtered and concentrated 
to afford the product N-benzyl-2-chloroacetamide 17 as a yellow 
solid (1.380 g, 7.52 mmol, 80.5%). M.Pt: 87-90 °C (lit. 91-92 °C).33 ߜH  
(400 MHz, CDCl3): 4.12 (2H, s, CH2), 4.50 (2H, d, J = 5.6 Hz, CH2), 6.87 
(1H, bs, NH), 7.38-7.29 (5H, m, ArH). ߜC (100MHz, CDCl3): 42.7, 44.0, 
127.9, 127.9, 129, 137.3, 165.9. IR (NEAT) ʆA? ? ? ? ?  ? ? ? ?  ? ? ? ?  ? ? ? ? ?
1234, 1550, 1645, 3275. m/z (APCI) calcd for C9H11ClNO [M+H]+: 
184.0524, found: 184.0524. 
Sodium hydride (60% in oil, 1.1 equiv, 0.33 g, 8.25 mmol) was 
washed with dry hexane (2 x 10 mL) and the hexane was removed. 
Dry THF (15 mL) was added to the sodium hydride and cooled down 
to 0 °C and a solution of 17 (1.0 equiv, 1.380 g, 7.52 mmol) in dry 
THF (25 mL) was slowly added. 
The resulting mixture was stirred from 0 °C to RT for 17 h. The 
mixture was quenched with water (50 ml). The non-soluble solid in 
water was filtered and the filtrate was extracted with DCM (2 x 30 
ml). The combined organic phases and solid previously filtered were 
concentrated at ƺĐŚŝ. The crude product was dissolved into DCM 
and purified by column chromatography on silica gel using 
DCM/MeOH (97%/3%). 
1,4-Dibenzylpiperazine-2,5-dione 8 was obtained as an off-white 
solid (0.476 g, 1.62 mmol, 43%). M.Pt: 94-95 °C (lit. 95-97 °C).34 ߜH  
(400 MHz, CDCl3): 3.96 (4H, s, CH2), 4.58 (4H, s, CH2), 7.28-7.26 (4H, 
m, ArH), 7.37-7.31 (6H, m, ArH). ߜC (100MHz, CDCl3): 49.3, 49.4, 
128.3, 128.7, 129.1, 135.1, 163.4. IR (NEAT) ʆ A?  ? ? ? ?  ? ? ? ?  ? ? ? ? ?
1160, 1275, 1328, 1483, 1643. m/z (APCI) calcd for C19H19N2O2 
[M+H]+: 295.1441, found: 295.1442. 
 
Preparation of 1,4-diphenethylpiperazine-2,5-dione 9 [R = 
(CH2)2Ph] 
To a solution of 2-phenylethan-1-amine 14 (1.0 equiv, 1.0 g, 8.25 
mmol) and triethylamine (1.1 equiv, 1.4 mL, 9.08 mmol) in DCM (30 
mL) was slowly added chloroacetyl chloride (1.1 equiv, 0.73 mL, 
9.08 mmol). 
After addition, the mixture was stirred at RT for 45 min and 
quenched with water (20 mL) and extracted with DCM (3 x 20 mL). 
The combined organic phases were washed with hydrochloric acid 
(2M, 20 mL) and with a saturated solution of NaHCO3 (20 mL). 
The organic phase was dried over Na2SO4, filtered and concentrated 
to afford the product 2-chloro-N-phenylacetamide 18 as a brown 
solid (1.275 g, 6.45 mmol, 78.2%). M.Pt: 60-61 °C (lit. 66-67 °C).35 ߜH  
(400 MHz, CDCl3): 2.85 (2H, t, J = 6.8 Hz, CH2), 3.57 (2H, q, J = 6.8 Hz, 
CH2), 4.02 (2H, s, CH2), 6.60 (1H, bs, NH), 7.21 (2H, m, ArH), 7.25 
(1H, m, ArH), 7.33 (2H, m, ArH). ߜC (100MHz, CDCl3): 35.6, 41.1, 
42.8, 126.9, 128.9, 138.5, 165.86. IR (NEAT) ʆ A?  ? ? ? ?  ? ? ? ?  ? ? ? ? ?
1188, 1260, 1541, 1643, 3335. m/z (APCI) calcd for C10H13ClNO 
[M+H]+: 198.0680, found: 198.0680. 
Sodium hydride (60% in oil, 1.0 equiv, 258 mg, 6.45 mmol) was 
washed with dry hexane (2 x 10 mL) and the hexane was removed. 
Dry THF (20 mL) was added to the sodium hydride and cooled down 
to 0 °C and a solution of 18 (1.0 equiv, 1.275 g, 6.45 mmol) in dry 
THF (30 mL) was slowly added. 
The resulting mixture was stirred from 0 °C to RT for 17 h. The 
mixture was quenched with water (30 ml) and extracted with DCM 
(4 x 30 ml). The combined organic phases were concentrated at 
ƺĐŚŝ. The crude product was dissolved into DCM and purified by 
column chromatography on silica gel using DCM/MeOH (98%/2%). 
1,4-diphenethylpiperazine-2,5-dione 9 was obtained as a beige solid 
(588 mg, 1.82 mmol, 56.4%). M.Pt.: 205-207 °C (lit. 210 °C).36 ߜH  
(400 MHz, CDCl3): 2.88 (4H, t, J = 7.6 Hz, CH2), 3.60 (4H, t, J = 7.6 Hz, 
CH2), 3.78 (4H, s, CH2), 7.19 (4H, m, ArH), 7.24 (2H, m, ArH), 7.31 
(4H, m, ArH). ߜC (100MHz, CDCl3): 33.3, 48.1, 50.9, 127.0, 128.8, 
 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?/Z ?Ed ?ʆA? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?  ?
1429, 1485, 1643, 2938. m/z (APCI) calcd for C20H23N2O2 [M+H]+: 
323.1754, found: 323.1758.  
 
Preparation of 1,4-bis(3-phenylpropyl)piperazine-2,5-dione 10 [R = 
(CH2)3Ph] 
To a solution of 3-phenylpropan-1-amine 15 (1.0 equiv, 1.0 g, 7.40 
mmol) and triethylamine (1.1 equiv, 1.14 mL, 8.12 mmol) in DCM 
(30 mL) was slowly added chloroacetyl chloride (1.1 equiv, 0.65 mL, 
8.12 mmol). After addition, the mixture was stirred at RT for 30 min 
and quenched with water (20 mL) and extracted with DCM (3 x 20 
mL). The combined organic phases were washed with a 2M solution 
of HCl in water (20 mL) and with a saturated solution of NaHCO3 (20 
mL). The organic phase was dried over Na2SO4, filtered and 
concentrated to afford the product 2-chloro-N-(3-
phenylpropyl)acetamide 19 as an orange oil (1.167 g, 5.51 mmol, 
74.5%). ߜH  (400 MHz, CDCl3): 1.90 (2H, qu, J = 7.6 Hz, CH2), 2.68 (2H, 
t, J = 7.6 Hz, CH2), 3.50 (2H, q, J = 6.0 Hz, CH2), 4.02 (2H, s, CH2), 6.56 
(1H, bs, NH), 7.20 (3H, m, ArH), 7.30 (2H, m, ArH). ߜC (100MHz, 
CDCl3): 30.9, 33.3, 39.6, 42.8, 126.3, 128.5, 128.7, 141.2, 166.0. IR 
 ?Ed ?ʆA? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?m/z (APCI) calcd 
for C11H15ClNO [M+H]+: 212.0837, found: 212.0835. 
Sodium hydride (60% in oil, 1.0 equiv, 220.5 mg, 5.51 mmol) was 
washed with dry hexane (2 x 10 mL) and the hexane was removed. 
Dry THF (20 mL) was added to the sodium hydride and cooled down 
to 0 °C and a solution of 19 (1.0 equiv, 1.167 g, 5.51 mmol) in dry 
THF (30 mL) was slowly added. The resulting mixture was stirred 
from 0 °C to RT for 22 h. The mixture was quenched with water (30 
ml) and extracted with DCM (4 x 30 ml). The combined organic 
phases were concentrated at rotavap. The crude product was 
dissolved into DCM and purified by column chromatography on 
silica gel using DCM/MeOH (98%/2%). 1,4-bis(3-
phenepropyl)piperazine-2,5-dione 10 was obtained as a pale yellow 
solid (604 mg, 1.72 mmol, 62.6%). M.Pt.: 115-118 °C (no lit. value). ߜH (400 MHz, CDCl3): 1.90 (4H, qt, J = 7.2 Hz, CH2), 2.64 (4H, t, J = 7.6 
Hz, CH2), 3.42 (4H, t, J = 7.6 Hz, CH2), 3.85 (4H, s, CH2), 7.19 (6H, m, 
ArH), 7.29 (4H, m, ArH). ߜC (100MHz, CDCl3): 28.1, 33.2, 45.9, 50.1, 
 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?/Z ?Ed ?ʆA? ? ? ? ?  ? ?  ? ? ? ? ?  ? ?
1024, 1487, 1647, 2932, 3292. m/z (APCI) calcd for C22H27N2O2 
[M+H]+: 351.2067, found: 351.2064.  
 
Coupling Reactions of Aryl Iodides and Bromides with Benzene 
(Table 1 and Table 2) 
 
General Reaction Conditions 
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All reactions were performed on a 1.0 mmol scale of the aryl halide. 
The mixture of the aryl halide (1.0 mmol), additive (0.1 mmol) and 
potassium tert-butoxide (337 mg, 3.0 mmol) in 10 mL of benzene 
was sealed in a 15 mL pressure tube in glovebox. The tube was 
removed from the glovebox and heated at 130 °C for 18 h behind a 
shield. After cooling to room temperature, the reaction was 
quenched by water (30 mL). The mixture was extracted with diethyl 
ether (3 x 30 mL). The combined organic layers were dried over 
sodium sulfate, filtered and concentrated. The residue was purified 
by column chromatography eluting with hexane when R = H, Me 
and with Et2O (2%) in hexane when R = OMe. 
 
Substrate: iodobenzene 25, Additive:  1,4-diphenylpiperazine-2,5-
dione 7 (Table 1, Entry 1) 
Iodobenzene 25 (0.204 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.026 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded biphenyl 37 as a white 
solid (123.4 mg, 0.800 mmol, 80.0%). M.Pt: 69-71 °C (lit. 70-71 °C).37 ߜH (400 MHz, CDCl3): 7.35 (2H, m, ArH), 7.44 (4H, m, ArH), 7.60 (4H, 
m, ArH). ߜC (100MHz, CDCl3): 127.3, 127.4, 128.9, 141.4. IR (NEAT) ʆ
= 694, 725, 902, 1004, 1429, 1475, 2924, 3034, 3061. m/z (APCI) 
calcd for C12H11 [M+H]+: 155.0855, found: 155.0851. 
 
Substrate: iodobenzene 25, Additive: 1,4-dibenzylpiperazine-2,5-
dione 8 (Table 1, Entry 2) 
Iodobenzene 25 (0.204 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded biphenyl 37 as a white 
solid (92.5 mg, 0.600 mmol, 60.0%). NMR spectra details as above. 
 
Substrate: iodobenzene 25, Additive: 1,4-diphenethylpiperazine-
2,5-dione 9 (Table 1, Entry 3) 
Iodobenzene 25 (0.204 g, 1.0 mmol) was treated with 1,4-
diphenethylpiperazine-2,5-dione 9 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded biphenyl 37 as 
a white solid (114.1 mg, 0.740 mmol, 74.0%). NMR spectra details 
as above. 
 
Substrate: iodobenzene 25, Additive: 1,4-bis(3-phenylpropyl)-
piperazine-2,5-dione 10 (Table 1, Entry 4) 
Iodobenzene 25 (0.204 g, 1.0 mmol) was treated with 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (0.035 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded biphenyl 37 as 
a white solid (107.9 mg, 0.700 mmol, 70.0%). NMR spectra details 
as above. 
 
Substrate: 2-iodoanisole 26, Additive:  1,4-diphenylpiperazine-2,5-
dione 7 (Table 1, Entry 5) 
2-iodoanisole 26 (0.234 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.026 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 2-methoxy- ? ? ? ?-
biphenyl 38 as a colourless oil (118.1 mg, 0.640 mmol, 64.0%). ߜH  
(400 MHz, CDCl3): 3.87 (3H, s, CH3), 7.06 (1H, m, ArH), 7.11 (1H, m, 
ArH), 7.37-7.42 (3H, m, ArH), 7.48 (2H, m, ArH), 7.62 (2H, m, ArH). ߜC (100MHz, CDCl3): 55.6, 111.4, 120.9, 127.0, 128.0, 128.7, 129.6, 
130.8, 131.0, 138.6, 156.6. IR (NEAT) ʆA? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
1234, 1257, 1429, 1481, 2833, 3059. m/z (APCI) calcd for C13H12O 
[M]+: 184.0883, found: 184.0878. 
 
Substrate: 2-iodoanisole 26, Additive: 1,4-dibenzylpiperazine-2,5-
dione 8 (Table 1,Entry 6) 
2-Iodoanisole 26 (0.234 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 2-methoxy- ? ? ? ?-
biphenyl 38 as a colourless oil (94.0 mg, 0.510 mmol, 51.0%). NMR 
spectra details as above. 
 
Substrate: 2-iodoanisole 26, Additive: 1,4-diphenethylpiperazine-
2,5-dione 9 (Table 1, Entry 7) 
2-Iodoanisole 26 (0.234 g, 1.0 mmol) was treated with 1,4-
diphenethylpiperazine-2,5-dione 9 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 2-methoxy-
 ? ? ? ?-biphenyl 38 as a colourless oil (108.7 mg, 0.590 mmol, 59.0%). 
NMR spectra details as above. 
 
Substrate: 2-iodoanisole 26, Additive: 1,4-bis(3-phenylpropyl)-
piperazine-2,5-dione 10 (Table 1, Entry 8) 
2-iodoanisole 26 (0.234 g, 1.0 mmol) was treated with 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (0.035 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 2-methoxy-
 ? ? ? ?-biphenyl 38 as a colourless oil (117.9 mg, 0.640 mmol, 64.0%). 
NMR spectra details as above. 
 
Substrate: 3-iodoanisole 27, Additive:  1,4-diphenylpiperazine-2,5-
dione 7 (Table 1, Entry 9) 
3-Iodoanisole 27 (0.234 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.026 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 3-methoxy- ? ? ? ?-
biphenyl 39 as a colourless oil (111.6 mg, 0.610 mmol, 61.0%). ߜH  
(400 MHz, CDCl3): 3.88 (3H, s, CH3), 6.92 (1H, m, ArH), 7.15 (1H, m, 
ArH), 7.20 (1H, m, ArH), 7.35-7.39 (2H, m, ArH), 7.45 (2H, m, ArH), 
7.61 (2H, m, ArH). ߜC (100MHz, CDCl3): 55.4, 112.8, 113.0, 119.8, 
127.3, 127.5, 128.8, 129.8, 141.2, 142.9, 160.1. IR (NEAT) ʆA?  ? ? ? ?
754, 850, 862, 1018, 1037, 1053, 1211, 1294, 1419, 1477, 1571, 
1597, 2833, 3057.  m/z (APCI) calcd for C13H12O [M]+: 184.0883, 
found: 184.0878 
 
Substrate: 3-iodoanisole 27, Additive: 1,4-dibenzylpiperazine-2,5-
dione 8 (Table 1, Entry 10) 
3-Iodoanisole 27 (0.234 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 3-methoxy- ? ? ? ?-
biphenyl 39 as a colourless oil (90.3 mg, 0.490 mmol, 49.0%). NMR 
spectra details as above. 
 
Substrate: 3-iodoanisole 27, Additive: 1,4-diphenethylpiperazine-
2,5-dione 9 (Table 1, Entry 11) 
3-Iodoanisole 27 (0.234 g, 1.0 mmol) was treated with 1,4-
diphenethylpiperazine-2,5-dione 9 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 3-methoxy-
 ? ? ? ?-biphenyl 39 as a colourless oil (129.0 mg, 0.700 mmol, 70.0%). 
NMR spectra details as above. 
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Substrate: 3-iodoanisole 27, Additive: 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (Table 1, Entry 12) 
3-Iodoanisole 27 (0.234 g, 1.0 mmol) was treated with 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (0.035 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 3-methoxy-
 ? ? ? ?-biphenyl 39 as a colourless oil (127.1 mg, 0.690 mmol, 69.0%). 
NMR spectra details as above. 
 
Substrate: 4-iodoanisole 28, Additive:  1,4-diphenylpiperazine-2,5-
dione 7 (Table 1, Entry 13) 
4-Iodoanisole 28 (0.234 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.026 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 4-methoxy- ? ? ? ?-
biphenyl 40 as a white solid (112.4 mg, 0.610 mmol, 61.0%). M.Pt: 
84-85 °C (lit. 84-85 °C).38 ߜH (400 MHz, CDCl3): 3.86 (3H, s, CH3), 6.98 
(2H, m, ArH), 7.30 (1H, m, ArH), 7.42 (2H, m, ArH), 7.51-7.57 (4H, m, 
ArH). ߜC (100MHz, CDCl3): 55.5, 114.4, 126.8, 126.9, 128.3, 128.9, 
133.9, 141.0, 159.3. IR (NEAT) ʆA? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
1247, 1483, 1604, 2835, 2962, 3003, 3034, 3066. m/z (APCI) calcd 
for C13H12O [M]+: 184.0883, found: 184.0878.  
 
Substrate: 4-iodoanisole 28, Additive: 1,4-dibenzylpiperazine-2,5-
dione 8 (Table 1, Entry 14) 
4-Iodoanisole 28 (0.234 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 4-methoxy- ? ? ? ?-
biphenyl 39 as a white solid (117.9 mg, 0.640 mmol, 64.0%). NMR 
spectra details as above. 
 
Substrate: 4-iodoanisole 28, Additive: 1,4-diphenethylpiperazine-
2,5-dione 9 (Table 1, Entry 15) 
4-Iodoanisole 28 (0.234 g, 1.0 mmol) was treated with 1,4-
diphenethylpiperazine-2,5-dione 9 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 4-methoxy-
 ? ? ? ?-biphenyl 40 as a white solid (147.4 mg, 0.800 mmol, 80.0%). 
NMR spectra details as above. 
 
Substrate: 4-iodoanisole 28, Additive: 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (Table 1, Entry 16) 
4-Iodoanisole 28 (0.234 g, 1.0 mmol) was treated with 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (0.035 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 3-methoxy-
 ? ? ? ?-biphenyl 40 as a white solid (132.6 mg, 0.720 mmol, 72.0%). 
NMR spectra details as above. 
 
Substrate: 2-iodotoluene 29, Additive:  1,4-diphenylpiperazine-
2,5-dione 7 (Table 1, Entry 17) 
2-Iodotoluene 29 (0.218 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.026 g, 0.1 mmol), KOtBu (0.337 
mg, 3.0 mmol) in benzene (10 mL) and afforded 2-methyl- ? ? ? ?-
biphenyl 41 as a colourless oil (116.0 mg, 0.690 mmol, 69.0%). ߜH 
(400 MHz, CDCl3): 2.33 (3H, s, CH3), 7.30 (3H, m, ArH), 7.37 (3H, m, 
ArH), 7.44-7.66 (3H, m, ArH). ߜC (100MHz, CDCl3): 20.6, 125.9, 
126.9, 127.3, 127.4, 128.2, 128.9, 129.3, 129.9, 130.4, 135.5, 142.1, 
142.2. IR (NEAT) ʆ A?  ? ? ? ?  ? ? ? ?  ? ? ? ?  ? ? ? ?  ? ? ? ? ?  ? ? ? ? ?m/z (APCI) 
calcd for C13H12 [M]+: 168.0934, found: 168.0930. 
 
Substrate: 2-iodotoluene 29, Additive: 1,4-dibenzylpiperazine-2,5-
dione 8 (Table 1, Entry 18) 
2-Iodotoluene 29 (0.218 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 2-methyl- ? ? ? ?-biphenyl 
41 as a colourless oil (74.0 mg, 0.440 mmol, 44.0%). NMR spectra 
details as above. 
 
Substrate: 2-iodotoluene 29, Additive: 1,4-diphenethylpiperazine-
2,5-dione 9 (Table 1, Entry 19) 
2-Iodotoluene 29 (0.218 g, 1.0 mmol) was treated with 1,4-
diphenethylpiperazine-2,5-dione 9 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 2-methyl- ? ? ? ?-
biphenyl 41 as a colourless oil (95.9 mg, 0.570 mmol, 57.0%). NMR 
spectra details as above. 
 
Substrate: 2-iodotoluene 29, Additive: 1,4-bis(3-phenylpropyl)-
piperazine-2,5-dione 10 (Table 1, Entry 20) 
2-Iodotoluene 29 (0.218 g, 1.0 mmol) was treated with 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 2-methyl- ? ? ? ?-
biphenyl 41 as a colourless oil (94.2 mg, 0.560 mmol, 56.0%). NMR 
spectra details as above. 
 
Substrate: 3-iodotoluene 30, Additive:  1,4-diphenylpiperazine-
2,5-dione 7 (Table 1, Entry 21) 
3-Iodotoluene 30 (0.218 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.026 g, 0.1 mmol), KOtBu (0.337 
mg, 3.0 mmol) in benzene (10 mL) and afforded 3-methyl- ? ? ? ?-
biphenyl 42 as a colourless oil (107.7 mg, 0.640 mmol, 64%). ߜH (400 
MHz, CDCl3): 2.48 (3H, s, CH3), 7.22 (1H, m, ArH), 7.39 (2H, m, ArH), 
7.47 (4H, m, ArH), 7.64 (2H, m, ArH). ߜC (100MHz, CDCl3): 21.7, 
124.4, 127.3, 128.1, 128.8, 128.9, 138.5, 141.4, 141.5. IR (NEAT) ʆA?
615, 696, 750, 1481, 1599, 2918, 3030. m/z (APCI) calcd for C13H12 
[M]+: 168.0934, found: 168.0930. 
 
Substrate: 3-iodotoluene 30, Additive: 1,4-dibenzylpiperazine-2,5-
dione 8 (Table 1, Entry 22) 
3-Iodotoluene 30 (0.218 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 3-methyl- ? ? ? ?-biphenyl 
42 as a colourless oil (95.9 mg, 0.570 mmol, 57.0%). NMR spectra 
details as above. 
 
Substrate: 3-iodotoluene 30, Additive: 1,4-diphenethylpiperazine-
2,5-dione 9 (Table 1, Entry 23) 
3-Iodotoluene 30 (0.218 g, 1.0 mmol) was treated with 1,4-
diphenethylpiperazine-2,5-dione 9 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 3-methyl- ? ? ? ?-
biphenyl 42 as a colourless oil (117.8 mg, 0.700 mmol, 70.0%). NMR 
spectra details as above. 
 
Substrate: 3-iodotoluene 30, Additive: 1,4-bis(3-phenylpropyl)-
piperazine-2,5-dione 10 (Table 1, Entry 24) 
3-Iodotoluene 30 (0.218 g, 1.0 mmol) was treated with 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 3-methyl- ? ? ? ?-
Journal Name  COMMUNICATION 
This journal is © The Royal Society of Chemistry 20xx Org. Biomol. Chem ., 2013, 00, 1-3 | 9 
Please do not adjust margins 
Please do not adjust margins 
biphenyl 42 as a colourless oil (112.7 mg, 0.670 mmol, 67.0%). NMR 
spectra details as above. 
 
Substrate: 4-iodotoluene 31, Additive:  1,4-diphenylpiperazine-
2,5-dione 7 (Table 1, Entry 25) 
4-Iodotoluene 31 (0.218 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.026 g, 0.1 mmol), KOtBu (0.337 
mg, 3.0 mmol) in benzene (10 mL) and afforded 4-methyl- ? ? ? ?-
biphenyl 43 as a colourless solid (100.9 mg, 0.060 mmol, 60%). 
M.Pt: 45-47 °C (lit. 46-47 °C).39 ߜH  (400 MHz, CDCl3): 2.41 (3H, s, 
CH3), 7.26 (2H, m, ArH), 7.33 (1H, m, ArH), 7.43 (2H, m, ArH), 7.51 
(2H, m, ArH), 7.59 (2H, m, ArH). ߜC (100MHz, CDCl3): 21.2, 127.1, 
128.8, 129.6, 137.2, 138.5, 141.3. IR (NEAT) ʆA? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
1377, 1485, 2856, 2916, 3030. m/z (APCI) calcd for C13H13 [M+H]+: 
169.1012, found: 169.1011. 
 
Substrate: 4-iodotoluene 31, Additive: 1,4-dibenzylpiperazine-2,5-
dione 8 (Table 1, Entry 26) 
4-iodotoluene 31 (0.218 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 4-methyl- ? ? ? ?-biphenyl 
43 as a colourless solid (100.9 mg, 0.600 mmol, 60.0%). NMR 
spectra details as above. 
Substrate: 4-iodotoluene 31, Additive: 1,4-diphenethylpiperazine-
2,5-dione 9 (Table 1, Entry 27) 
4-iodotoluene 31 (0.218 g, 1.0 mmol) was treated with 1,4-
diphenethylpiperazine-2,5-dione 9 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 4-me thyl- ? ? ? ?-
biphenyl 43 as a colourless solid (131.2 mg, 0.780 mmol, 78.0%). 
NMR spectra details as above. 
 
Substrate: 4-iodotoluene 31, Additive: 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (Table 1, Entry 28) 
4-iodotoluene 31 (0.218 g, 1.0 mmol) was treated with 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 4-methyl- ? ? ? ?-
biphenyl 43 as a colourless solid (114.4 mg, 0.680 mmol, 68.0%). 
NMR spectra details as above. 
 
Substrate: bromobenzene 32, Additive:  1,4-diphenylpiperazine-
2,5-dione 7 (Table 2, Entry 1) 
Bromobenzene 32 (0.157 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.026 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded biphenyl 37 as a white 
solid (21.6 mg, 0.140 mmol, 14.0%). NMR spectra details as above. 
 
Substrate: bromobenzene 32, Additive: 1,4-dibenzylpiperazine-
2,5-dione 8 (Table 2, Entry 2) 
Bromobenzene 32 (0.157 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded biphenyl 37 as a white 
solid (104.9 mg, 0.680 mmol, 68.0%). NMR spectra details as above. 
 
Substrate: bromobenzene 32, Additive: 1,4-diphenethylpiperazine 
-2,5-dione 9 (Table 2, Entry 3) 
Bromobenzene 32 (0.157 g, 1.0 mmol) was treated with 1,4-
diphenethylpiperazine-2,5-dione 9 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded biphenyl 37 as 
a white solid (49.3 mg, 0.320 mmol, 32.0%). NMR spectra details 
were as above. 
 
Substrate: bromobenzene 32, Additive: 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (Table 2, Entry 4) 
Bromobenzene 32 (0.157 g, 1.0 mmol) was treated with 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (0.035 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded biphenyl 37 as 
a white solid (49.3 mg, 0.320 mmol, 32.0%). NMR spectra details as 
above. 
 
Substrate: 2-bromoanisole 33, Additive:  1,4-diphenylpiperazine-
2,5-dione 7 (Table 2, Entry 5) 
2-Bromoanisole 33 (0.184 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.026 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 2-methoxy- ? ? ? ?-
biphenyl 38 as a colourless oil (66.3 mg, 0.360 mmol, 36.0%). NMR 
spectra details as above. 
 
Substrate: 2-bromoanisole 33, Additive: 1,4-dibenzylpiperazine-
2,5-dione 8 (Table 2, Entry 6) 
2-bromoanisole 33 (0.184 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 2-methoxy- ? ? ? ?-
biphenyl 38 as a colourless oil (92.1 mg, 0.500 mmol, 50.0%). NMR 
spectra details as above. 
 
Substrate: 2-bromoanisole 33, Additive: 1,4-diphenethylpiperazine 
-2,5-dione 9 (Table 2, Entry 7) 
2-Bromoanisole 33 (0.184 g, 1.0 mmol) was treated with 1,4-
diphenethylpiperazine-2,5-dione 9 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 2-methoxy-
 ? ? ? ?-biphenyl 38 as a colourless oil (88.4 mg, 0.480 mmol, 48.0%). 
NMR spectra details as above. 
 
Substrate: 2-bromoanisole 33, Additive: 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (Table 2, Entry 8) 
2-Bromoanisole 33 (0.184 g, 1.0 mmol) was treated with 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (0.035 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 2-methoxy-
 ? ? ? ?-biphenyl 38 as a colourless oil (108.7 mg, 0.590 mmol, 59.0%). 
NMR spectra details as above. 
 
Substrate: 3-bromoanisole 34, Additive:  1,4-diphenylpiperazine-
2,5-dione 7 (Table 2, entry 9) 
3-Bromoanisole 34 (0.184 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.026 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 3-methoxy- ? ? ? ?-
biphenyl 39 as a colourless oil (3.7 mg, 0.020 mmol, 2.0%). NMR 
spectra details as above. 
 
Substrate: 3-bromoanisole 34, Additive:  1,4-dibenzylpiperazine-
2,5-dione 8 (Table 2, Entry 10) 
3-Bromoanisole 34 (0.184 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 3-methoxy- ? ? ? ?-
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biphenyl 39 as a colourless oil (3.7 mg, 0.020 mmol, 2.0%). NMR 
spectra details as above. 
 
Substrate: 3-bromoanisole 34, Additive: 1,4-diphenethylpiperazine 
-2,5-dione 9 (Table 2, Entry 11) 
3-Bromoanisole 34 (0.184 g, 1.0 mmol) was treated with 1,4-
diphenethylpiperazine-2,5-dione 9 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 3-methoxy-
 ? ? ? ?-biphenyl 39 as a colourless oil (3.7 mg, 0.020 mmol, 2.0%). 
NMR spectra details as above. 
 
Substrate: 3-bromoanisole 34, Additive: 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (Table 2, Entry 12) 
3-Bromoanisole 34 (0.184 g, 1.0 mmol) was treated with 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (0.035 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 3-methoxy-
 ? ? ? ?-biphenyl 39 as a colourless oil (3.7 mg, 0.020 mmol, 2.0%). 
NMR spectra details as above. 
 
Substrate: 4-bromoanisole 35, Additive:  1,4-diphenylpiperazine-
2,5-dione 7 (Table 2, Entry 13) 
4-Bromoanisole 35 (0.184 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.026 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 4-methoxy- ? ? ? ?-
biphenyl 40 as a white solid (23.9 mg, 0.130 mmol, 13.0%). NMR 
spectra details as above. 
 
Substrate: 4-bromoanisole 35, Additive:  1,4-dibenzylpiperazine-
2,5-dione 8 (Table 2, Entry 14) 
4-Bromoanisole 35 (0.184 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 4-methoxy- ? ? ? ?-
biphenyl 40 as a white solid (103.2 mg, 0.560 mmol, 56.0%). NMR 
spectra details as above. 
 
Substrate: 4-bromoanisole 35, Additive: 1,4-diphenethylpiperazine 
-2,5-dione 9 (Table 2, Entry 15) 
4-bromoanisole 35 (0.184 g, 1.0 mmol) was treated with 1,4-
diphenethylpiperazine-2,5-dione 9 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 4-methoxy-
 ? ? ? ?-biphenyl 40 as a white solid (38.7 mg, 0.210 mmol, 21.0%). 
NMR spectra details as above. 
 
Substrate: 4-bromoanisole 35, Additive: 1,4-bis(3-phenylpropyl)-
piperazine-2,5-dione 10 (Table 2, Entry 16) 
4-Bromoanisole 35 (0.184 g, 1.0 mmol) was treated with 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (0.035 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 4-methoxy-
 ? ? ? ?-biphenyl 40 as a white solid (53.4 mg, 0.290 mmol, 29.0%). 
NMR spectra details as above. 
 
Substrate: 4-bromotoluene 36, Additive:  1,4-diphenylpiperazine-
2,5-dione 7 (Table 2, Entry 17) 
4-Bromotoluene 36 (0.171 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.026 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 4-methyl- ? ? ? ?-biphenyl 
43 as a colourless solid (62.2 mg, 0.370 mmol, 37.0%). NMR spectra 
details as above. 
 
Substrate: 4-bromotoluene 36, Additive:  1,4-dibenzylpiperazine-
2,5-dione 8 (Table 2, Entry 18) 
4-bromotoluene 36 (0.171 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded 4-methyl- ? ? ? ?-biphenyl 
43 as a colourless solid (79.1 mg, 0.470 mmol, 47.0%). NMR spectra 
details as above. 
 
Substrate: 4-bromotoluene 36, Additive: 1,4-diphenethyl-
piperazine-2,5-dione 9 (Table 2, Entry 19) 
4-Bromotoluene 36 (0.171 g, 1.0 mmol) was treated with 1,4-
diphenethylpiperazine-2,5-dione 9 (0.032 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 4-methyl- ? ? ? ?-
biphenyl 43 as a colourless solid (48.8 mg, 0.290 mmol, 29.0%). 
NMR spectra details as above. 
 
Substrate: 4-bromotoluene 36, Additive: 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (Table 2, Entry 20) 
4-Bromotoluene 36 (0.171 g, 1.0 mmol) was treated with 1,4-bis(3-
phenylpropyl)piperazine-2,5-dione 10 (0.035 g, 0.1 mmol), KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded 4-methyl- ? ? ? ?-
biphenyl 43 as a colourless solid (62.2 mg, 0.370 mmol, 37.0%). 
NMR spectra details as above. 
 
Benzyne Formation and tert-Butoxide Nucleophilic Addition 
(Scheme 5) 
 
General Reaction Conditions 
All reactions were performed on a 1.0 mmol scale of the aryl halide. 
The mixture of the aryl halide (1.0 mmol), additive (0.1 mmol) and 
potassium tert-butoxide (337 mg, 3.0 mmol) in 10 mL of benzene 
was sealed in a 15 mL pressure tube in glovebox. The tube was 
removed from the glovebox and heated at indicated temperature 
for indicated amount of time behind a shield. After cooling to room 
temperature, the reaction was quenched by water (30 mL). The 
mixture was extracted with diethyl ether (3 x 30 mL). The combined 
organic layers were dried over sodium sulfate, filtered and 
concentrated. 1,3,5-trimethoxybenzene was added to the crude 
product as an internal standard and 1H NMR of the resulting crude 
reactuion mixture was used to quantify the yields of the reactions. 
 
Substrate: 4-bromoanisole 35, Additive:  1,4-dibenzylpiperazine-
2,5-dione 8  
4-bromoanisole 35 (0.184 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL). Crude 1H NMR showed formation of 
4-methoxy- ? ? ? ?-biphenyl 40 (0.620 mmol, 62.0%), NMR spectra 
details as above, 1-(tert-butoxy)-3-methoxybenzene 44 (0.093 
mmol, 9%, ߜH (400 MHz, CDCl3): 1.36 (9H, s, OC(CH3)3), 3.78 (3H, s, 
OCH3), 6.55 (1H, t, J = 2.0 Hz, ArH), 6.60 (2H, m, ArH), 7.15 (1H, t, J = 
8.0 Hz, ArH)) and 1-(tert-butoxy)-4-methoxybenzene 46 (0.10 mmol, 
10%, ߜH (400 MHz, CDCl3): 1.31 (9H, s, OC(CH3)3), 3.78 (3H, s, OCH3), 
6.79 (2H, m, ArH), 6.92 (2H, m, ArH), data in accordance with 
literature for both isomers).40 
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Substrate: 4-bromoanisole 35, Additive:  1,4-dibenzylpiperazine-
2,5-dione 8  
4-bromoanisole 35 (0.184 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL). Crude 1H NMR showed formation of 
4-methoxy- ? ? ? ?-biphenyl 40 (0.290 mmol, 29.0%), 1-(tert-butoxy)-3-
methoxybenzene 44 (0.10 mmol, 10%) and 1-(tert-butoxy)-4-
methoxybenzene 46 (0.11 mmol, 11%). NMR spectra details as 
above. 
 
Substrate: bromobenzene 32, Additive:  1,4-dibenzylpiperazine-
2,5-dione 8  
Bromobenzene 32 (0.157 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL). Crude 1H NMR showed formation of 
biphenyl 37 (0.70 mmol, 70%), NMR spectra details as above, and 
tert-butoxybenzene 48 as a colourless liquid (0.08 mmol, 8%, ߜH 
(400 MHz, CDCl3): 1.35 (9H, s, OC(CH3)3), 6.99 (2H, m, ArH), 7.05 
(1H, m, ArH), 7.26 (2H, m, ArH) data in accordance with 
literature).40 
 
Substrate: bromobenzene 32, Additive:  1,4-dibenzylpiperazine-
2,5-dione 8  
Bromobenzene 32 (0.157 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL). Crude 1H NMR showed formation of 
biphenyl 37 (0.46 mmol, 46%) and tert-butoxybenzene 48 (0.10 
mmol, 10%). NMR spectra details as above. 
 
Substrate: chlorobenzene 49, Additive:  1,4-dibenzylpiperazine-
2,5-dione 8  
Chlorobenzene 49 (0.112 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL). Crude 1H NMR showed only 
formation of tert-butoxybenzene 48 (0.32 mmol, 32%). NMR 
spectra details as above. 
 
Substrate: 4-chloroanisole 50, Additive:  1,4-dibenzylpiperazine-
2,5-dione 8  
4-chloroanisole 50 (0.142 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL). Crude 1H NMR showed only 
formation of 1-(tert-butoxy)-3-methoxybenzene 44 (0.18 mmol, 
18%) and 1-(tert-butoxy)-4-methoxybenzene 46 (0.17 mmol, 17%). 
NMR spectra details as above. 
 
Substrate: 4-iodoanisole 28, Additive: 1,4-diphenylpiperazine-2,5-
dione 7  
4-iodoanisole 28 (0.234 g, 1.0 mmol) was treated with 1,4-diphenyl-
piperazine-2,5-dione 7 (0.026 g, 0.1 mmol), KOtBu (0.337 g, 3.0 
mmol) in benzene (10 mL). Crude 1H NMR showed formation of 4-
methoxy- ? ? ? ?-biphenyl 40 (0.740 mmol, 74.0%), 1-(tert-butoxy)-3-
methoxybenzene 44 (0.02 mmol, 2%) and 1-(tert-butoxy)-4-
methoxybenzene 46 (0.02 mmol, 2%). 
 
Coupling Reactions of 4-halobenzonitriles with Benzene (Scheme 
6) 
 
General Reaction Conditions 
All reactions were performed on a 1.0 mmol scale of the aryl halide. 
The mixture of the aryl halide (1.0 mmol), additive (0.1 mmol) and 
potassium tert-butoxide (337 mg, 3.0 mmol) in 10 mL of benzene 
was sealed in a 15 mL pressure tube in glovebox. The tube was 
removed from the glovebox and heated at 130 °C for 18 h behind a 
shield. After cooling to room temperature, the reaction was 
quenched by water (30 mL). The mixture was extracted with diethyl 
ether (3 x 30 mL). The combined organic layers were dried over 
sodium sulfate, filtered and concentrated. The residue was purified 
by column chromatography eluting with Et2O (10%) in hexane. 
 
Substrate: 4-iodobenzonitrile 51, Additive: 1,4-
diphenylpiperazine-2,5-dione 7 
4-iodobenzonitrile 51 (0.229 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.027 g, 0.1 mmol), KOtBu (0.337 g, 
 ? ? ? ŵŵŽů ? ŝŶ ďĞŶǌĞŶĞ  ? ? ? ŵ> ? ĂŶĚ ĂĨĨŽƌĚĞĚ  ? ? ? ? ?-biphenyl]-4-
carbonitrile 53 as a white solid (122.0 mg, 0.681 mmol, 68.1%). 
M.Pt: 83-86 °C (lit. 83-85 °C).41 ߜH (400 MHz, CDCl3): 7.42 (1H, m, 
ArH), 7.48 (2H, m, ArH), 7.59 (2H, m, ArH), 7.72 (4H, m, ArH). ߜC 
(100MHz, CDCl3): 111.1, 119.1, 127.4, 127.9, 128.8, 129.3, 132.8, 
139.4, 145.9. IR (NEAT) ʆA? 2224, 1602, 1481, 1065, 1041, 769, 697. 
m/z (EI) calcd for C13H9N [M]: 179.1, found: 179.1. 
 
Substrate: 4-bromobenzonitrile 52, Additive: 1,4-
diphenylpiperazine-2,5-dione 7 
4-bromobenzonitrile 52 (0.182 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.027 g, 0.1 mmol), KOtBu (0.337 g, 
3.0 mmol) in benzene (10 mL) and afforded an inseparable mixture 
of  ? ? ? ? ?-biphenyl]-4-carbonitrile 53 (14.4%) NMR spectra details as 
above, 4-(tert-butoxy)benzonitrile (8.5%), ߜH (400 MHz, CDCl3): 1.42 
(9H, s, OC(CH3)3), 7.04 (2H, m, ArH), 7.56 (2H, m, ArH), and 3-(tert-
butoxy)benzonitrile (9.9%), ߜH (400 MHz, CDCl3): 1.37 (9H, s, 
OC(CH3)3), 7.21 (1H, m, ArH), 7.27 (1H, m, ArH), 7.35 (2H, m, ArH). 
 
Substrate: 4-iodobenzonitrile 51, Additive: 1,4-dibenzylpiperazine-
2,5-dione 8 
4-iodobenzonitrile 51 (0.229 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
 ? ? ? ŵŵŽů ? ŝŶ ďĞŶǌĞŶĞ  ? ? ? ŵ> ? ĂŶĚ ĂĨĨŽƌĚĞĚ  ? ? ? ? ?-biphenyl]-4-
carbonitrile 53 as a white solid (135.0 mg, 0.753 mmol, 75.3%). 
NMR spectra details as above. 
 
Substrate: 4-bromobenzonitrile 52, Additive: 1,4-
dibenzylpiperazine-2,5-dione 8 
4-bromobenzonitrile 52 (0.182 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol), KOtBu (0.337 g, 
 ? ? ? ŵŵŽů ? ŝŶ ďĞŶǌĞŶĞ  ? ? ? ŵ> ? ĂŶĚ ĂĨĨŽƌĚĞĚ  ? ? ? ? ?-biphenyl]-4-
carbonitrile 53 as a white solid (96.0 mg, 0.536 mmol, 53.6%). NMR 
spectra details as above. 
 
Reactions of 4-halobenzotrifluorides with KOtBu (Scheme 7) 
 
General Reaction Conditions 
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All reactions were performed on a 1.0 mmol scale of the aryl halide. 
The mixture of the aryl halide (1.0 mmol), additive (0.1 mmol) and 
potassium tert-butoxide (337 mg, 3.0 mmol) in 10 mL of benzene 
was sealed in a 15 mL pressure tube in glovebox. The tube was 
removed from the glovebox and heated at 130 °C for 18 h behind a 
shield. After cooling to room temperature, the reaction was 
quenched by water (30 mL). The mixture was extracted with diethyl 
ether (3 x 30 mL). The combined organic layers were dried over 
sodium sulfate, filtered and concentrated. The residue was purified 
by column chromatography eluting with Et2O (1%) in hexane. 
 
Substrate: 4-iodobenzotrifluoride 54, Additive: 1,4-
diphenylpiperazine-2,5-dione 7 
4-iodobenzotrifluoride 54 (0.272 g, 1.0 mmol) was treated with 1,4-
diphenylpiperazine-2,5-dione 7 (0.027 g, 0.1 mmol) and KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded an inseparable 
mixture of 4-(tert-butoxy)benzotrifluoride 56 (0.216 mmol, 21.6%, ߜH (400 MHz, CDCl3): 1.39 (9H, s, OC(CH3)3), 7.06 (2H, d, J = 8.4 Hz, 
ArH), 7.53 (2H, d, J = 8.4 Hz, ArH)) and 3-(tert-
butoxy)benzotrifluoride 57 (0.196 mmol, 19.6%, ߜH (400 MHz, 
CDCl3): 1.37 (9H, s, OC(CH3)3), 7.15 (1H, m, ArH), 7.23 (1H, m, ArH), 
7.36 (2H, m, ArH), data in accordance with literature for both 
isomers).40 
 
Substrate: 4-bromobenzotrifluoride 55, Additive: 1,4-
diphenylpiperazine-2,5-dione 7 
4-bromobenzotrifluoride 55 (0.225 g, 1.0 mmol) was treated with 
1,4-diphenylpiperazine-2,5-dione 7 (0.027 g, 0.1 mmol) and KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded an inseparable 
mixture of 4-(tert-butoxy)benzotrifluoride 56 (0.171 mmol, 17.1%) 
and 3-(tert-butoxy)benzotrifluoride 57 (0.150 mmol, 15.0%). NMR 
spectra details as above. 
 
Substrate: 4-iodobenzotrifluoride 54, Additive: 1,4-
dibenzylpiperazine-2,5-dione 8 
4-iodobenzotrifluoride 54 (0.272 g, 1.0 mmol) was treated with 1,4-
dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol) and KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded an inseparable 
mixture of 4-(tert-butoxy)benzotrifluoride 56 (0.214 mmol, 21.4%) 
and 3-(tert-butoxy)benzotrifluoride 57 (0.166 mmol, 16.6%). NMR 
spectra details as above. 
 
Substrate: 4-bromobenzotrifluoride 55, Additive: 1,4-
dibenzylpiperazine-2,5-dione 8 
4-bromobenzotrifluoride 55 (0.225 g, 1.0 mmol) was treated with 
1,4-dibenzylpiperazine-2,5-dione 8 (0.029 g, 0.1 mmol) and KOtBu 
(0.337 g, 3.0 mmol) in benzene (10 mL) and afforded an inseparable 
mixture of 4-(tert-butoxy)benzotrifluoride 56 (0.244 mmol, 24.4%) 
and 3-(tert-butoxy)benzotrifluoride 57 (0.196 mmol, 19.6%). NMR 
spectra details as above. 
Acknowledgements 
We thank the University of Strathclyde for funding. Mass 
spectrometry data were acquired at the ESPRC UK National 
Mass Spectrometry Facility at Swansea University. 
 
References 
1  S. Yanagasawa, K. Ueda, T. Taniguchi and K. Itami Org. Lett. 
2008, 10, 4673-4676. 
2 Selected reviews on transition metal-free cross-coupling 
reactions: (a) C.-L. Sun, Z.-J. Shi, Chem. Rev. 2014, 114, 9219-
9280. (b) R. Narayan, K. Matcha, A. P. Antonchick, Chem. Eur. J. 
2015, 21, 14678-14693. (c) A. Studer, D. P. Curran, Angew. 
Chem. Int. Ed. 2016, 55, 58-102. (d) P. Liu, G. Zhang, P. Sun, Org. 
Biomol. Chem. 2016, 14, 10763-10777. 
3  C.-L. Sun, H. Li, D.-G. Yu, M. Yu, X. Zhou, X.-Y. Lu, K. Hunag, S.-F. 
Zheng, B.-J. Li and Z.-J. Shi, Nat. Chem. 2010, 2, 1044-1049. 
4  W. Liu, H. Cao, H. Zhang, H. Zhang, K. H. Chung, C. He, H. Wang, 
F. Y. Kwong and A. Lei, J. Am. Chem. Soc. 2010, 132, 16737-
16740. 
5  Y. Wu, P. Y. Choyand F. Y. Kwong, Org. Biomol. Chem. 2014, 12, 
6820-6823. 
6  E. Shirakawa, K.-I. Itoh, T. Higashino and T. Hayashi, J. Am. 
Chem. Soc. 2010, 132, 15537-15539. 
7  M. Rueping, M. Leiendecker, A. Das, T. Poisson and L. Bui, 
Chem. Commun. 2011, 47, 10629-10631. 
8  H. Liu, B. Yin, Z. Gao, Y. Li and H. Jiang, Chem. Commun. 2012, 
48, 2033-2035. 
9  D. S. Roman, Y. Takahashi and A. B. Charette, Org. Lett. 2011, 
13, 3242-3245. 
10  S. De, S. Ghosh, S. Bhunia, J. A. Shiekh and A. Bisai, Org. Lett. 
2012, 14, 4466-4469. 
11 K. Tanimoro, M. Ueno, K. Takeda, M. Kirihata and S. Tanimori, J. 
Org. Chem. 2012, 77, 7844-7849. 
12  W. Liu, F. Tian, X. Wang, H. Yu and Y. Bi, Chem. Commun. 2013, 
49, 2983-2985. 
13 W.-C. Chen; Y.-C. Hsu, W.-C. Shih, C.-Y. Lee, W.-H. Chuang, Y.-F. 
Tsai, P. P.-Y. Chen and T.-G. Ong, Chem. Commun. 2012, 48, 
6702-6704. 
14 S. Sharma, M. Kumar, V. Kumar and N. Kumar, Tetrahedron Lett. 
2013, 54, 4868-4871. 
15 J. Cuthbertson, V. J. Gray and J. D. Wilden, Chem. Commun. 
2014, 50, 2575-2578. 
16 H. Yi, A. Jutand and A. Lei, Chem. Commun. 2015, 51, 545-548. 
17 A. Studer, D. P. Curran, Angew. Chem. Int. Ed. 2011, 50, 5018-
5022. 
18 S. Zhou, G. M. Anderson, B. Mondal, E. Doni, V. Ironmonger, M. 
Kranz, T. Tuttle and J. A. Murphy, Chem. Sci. 2014, 5, 476-482. 
19 S. Zhou, E. Doni, G. M. Anderson, R. G. Kane, S. W. MacDougall, 
V. M. Ironmonger, T. Tuttle and, J. A. Murphy, J. Am. Chem. Soc. 
2014, 136, 17818-17826. 
20 J. P. Barham, G. Coulthard, K. J. Emery, E. Doni, F. Cumine, G. 
Nocera, M. P. John, L. E. A. Berlouis, T. McGuire, T. Tuttle and J. 
A. Murphy, J. Am. Chem. Soc. 2016, 138, 7402-7410. 
21 C. A. G. N. Montalbetti and V. Falque, Tetrahedron 2005, 61, 
10827-10852. 
22 Nonappa, K. Ahonen, M. Lahtinen and E. Kolehmainen, Green 
Chem. 2011, 13, 1203-1209. 
23 J. P. Barham, G. Coulthard, R. G. Kane, N. Delgado, M. P. John 
and J. A. Murphy, Angew. Chem. Int. Ed. 2016, 55, 4492-4496. 
24 E. Ceppi, W. Eckhardt and C. A. Grob, Tetrahedron Lett. 1973, 
14, 3627-3630. 
25 Calculations were performed using the Gaussian 09 software 
package. M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, 
M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. 
Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. 
Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, 
M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. 
Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. 
Montgomery Jr, J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. Heyd, 
E. N. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. 
Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. 
Iyengar, J. Tomasi, M. Cossi, N. Rega, N. J. Millam, M. Klene, J. E. 
Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, 
Journal Name  COMMUNICATION 
This journal is © The Royal Society of Chemistry 20xx Org. Biomol. Chem ., 2013, 00, 1-3 | 13 
Please do not adjust margins 
Please do not adjust margins 
R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. 
W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. 
Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. 
Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, D. J. Fox, 
Gaussian 09, Revision D.01, Gaussian, Inc., Wallingford, CT, USA, 
2009. 
26 (a) Calculations were made using the M06-2X functional. Y. Zhao, 
D. G. Truhlar, Acc. Chem. Res. 2008, 41, 157-167. (b) Elements 
were modelled using the aug-cc-pvdz basis set. T. H. Dunning, J. 
Chem. Phys. 1989, 90, 1007-1023. (c) The Conductor-like 
Polarizable Continuum Model, with the associated parameters 
of benzene as solvent, was used to model implicit solvation. V. 
Barone and M. Cossi, J. Phys. Chem. A 1998, 102, 1995-2001. M. 
Cossi, N. Rega, G. Scalmani and V. Barone, J. Comput. Chem. 
2003, 24, 669-681. 
27 (a) R. A. Marcus, J. Chem. Phys. 1965, 43, 679-701. (b) S. F. 
Nelsen, S. C. Blackstock and Y. Kim, J. Am. Chem. Soc. 1987, 109, 
677-682. 
28 (a) J. D. Roberts, C. W. Vaughan, L. A. Carlsmith and D. A. 
Semenow, J. Am. Chem. Soc. 1956, 78, 611-614. (b) J. H. Wotiz 
and F. Huba, J. Org. Chem. 1959, 24, 595-598. (c) Y. Dong, M. I. 
Lipschutz and T. D. Tilley, Org. Lett. 2016, 18, 1530-1533. 
29 E. Picazo, K. N. Houk and N. K. Garg, Tetrahedron Lett. 2015, 56, 
3511-3514. 
30 G. B. Bajracharya, O. Daugulis, Org. Lett. 2008, 10, 4625-4628. 
31  S. R. Yong, A. T. Ung, S. G. Pyne, B. W. Skelton and A. H.       
 White, Tetrahedron Lett. 2007, 63, 1191-1199. 
32  Y. Wen, X. Chen, H. Wen and X. Tang, Lett. Org. Chem. 2011, 
8, 732-736. 
33 A. L. Cardoso, C. Sousa, M. S. C. Henriques, J. A. Paixo, 
T.M.V.D. Pinho E Melo and K. Banert, Molecules 2015, 20, 
22351-22363. 
34 H. Morimoto, R. Fujiwara, Y. Shimizu, K. Morisaki, T. 
Ohshima, Org. Lett. 2014, 16, 2018-2021. 
35 V. Vecchietti, G. D. Clarke, R. Colle, G. Giardina, G. Petrone 
and M. Sbacchi, J. Med. Chem. 1991, 34, 2624-2633. 
36 Murnen, A. M.  Rosales, J. N. Jaworski, R. A. Segalman and R. 
N. Zuckermann, J. Am. Chem. Soc., 2010, 132, 16112-16119. 
37 J. Zhou, S. Yu, K. Cheng and C. Qi, J. Chem. Res. 2012, 36, 
672-674. 
38 J. Zeng, K. M. Liu and X. F. Duan, Org. Lett. 2013, 15, 5342-
5345. 
39 C. A. Parrish and S. L. Buchwald, J. Org. Chem. 2001, 66, 
2498-2500. 
40 D. P. DeCosta, A. Bennett, A. L. Pincock, J. A. Pincock, R. 
Stefanova, J. Org. Chem. 2000, 65, 4162-4168.  
41 Q. Di, J. Liang, Z. Zhitong, M. He, M. Fanyang, W. Xi, Z. Yan, 
W. Jianbo, J. Org. Chem. 2013, 78, 1923-1933. 
